Clinical Trial Update: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas [Phase 2]

View source ↗

Summary

Phase II open-label study of ixazomib (MLN9708) in relapsed/refractory cutaneous and peripheral T-cell lymphomas has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• MLN9708 (ixazomib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Lymphoma, T-Cell | Phase 2 | Status: COMPLETED | Results posted: 2017-11-13